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Abstract
Background: Morbidity and mortality following cardiac valve surgery is high. Immunity is an important contributor
to outcome. This study examines the relationship of staphylococcal and endotoxin antibody levels to outcome
following cardiac surgery.
Methods: Using enzyme-linked immunosorbent assays (ELISA), we measured pre-operative levels of antibodies to
endotoxin core (EndoCAb); 3 common staphylococcal epitopes and varicella on saved serum of 60 adult patients
scheduled to undergo elective primary surgical aortic valve replacement (AVR). Primary outcome measure was
post-operative length of stay (LOS) in hospital with secondary outcomes being development of infective complications,
length of stay on the intensive care unit (ICU) and 30-day mortality. Patients were quartiled according to antibody levels
and outcomes compared between the quartile groups using Mann-Whitney tests for length of stay and Fisher’s test for
development of infection.
Results: Sixty patients (34 M, 26 F) were recruited with mean age 73 years (IQR 66–78), mean body mass index (BMI) 27.
7 (IQR 25–31) and EuroSCORE II 1.44 (0.95–1.99). Those patients in the lower quartile for pre-operative antibody level had
a longer post-operative stay than the upper quartile. EndoCAb (median IgG level Q1 42.2 MU/ml vs Q4 256 MU/ml) 9 vs
6 days, p = 0.025; alpha-toxin (median IgG level Q1 63 U vs Q4 558 U) 10 vs 7 days, p = 0.034; teichoic acid (median IgG
level Q1 14 U vs Q4 419 U) 10 vs 8 days, p = 0.441; staphylococcal enterotoxin A (median IgG level Q1 55 U vs Q4 427 U)
9 vs 7 days, p = 0.865; varicella zoster (median IgG level Q1 1.325 U vs Q4 2.54 U) 8 vs 7 days, p = 1.0; and combined
antibody levels 10 vs 6 days, p = 0.017. There were no differences in the number developing post-operative infections
for each antibody type. The combined antibody analysis suggested a reduction in proportion of individuals developing
infection from the upper vs lower quartile: 0 vs 0.33, p = 0.042.
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Conclusions: This study again suggests the inverse relationship between endotoxin core antibody levels and outcome
following aortic valve surgery as well as suggesting a similar relationship with antibodies to staphylococcus. There is no
such relationship for antibody levels against an organism not providing a peri-operative threat. Understanding
this relationship may enable therapeutic manipulation of immune status, re-evaluation of risk and further investigation
of the low immune state.
Trial registration: The patients in this study are a sub-group of the RELIEF AS study.
ClinicalTrials.gov identifier NCT02174471.
Keywords: Cardiac surgical procedures, Core endotoxin, Immunity, Sepsis, Staphylococcus
Background
The risks of undergoing surgical replacement of the aor-
tic valve are not inconsiderable with a mortality of up to
5.6% (Kvidal et al., 2000), and a high morbidity burden
(Auensen et al., 2017).
Patients who experience complications following car-
diac surgery may well have prolonged recovery periods
as well as longer stay in hospital (Brown et al., 2008).
The risk factors for developing complications and early
mortality have been well described and commonly used
risk scoring systems (e.g. Parsonnet, EuroSCORE, Euro-
SCORE 2 (Parsonnet et al., 1989; Nashef et al., 2012;
Nashef et al., 1999)) highlight these when used to predict
the risk of adverse outcomes (Wang et al., 2014). Around
1–2% of patients undergoing cardiac surgery experience
infective complications with staphylococcal organisms,
and most of these do not have any of the known risk fac-
tors (Kanafani et al., 2009). Little, if anything, is known re-
garding the competence of the immune system in these
patients. Do those who experience adverse outcomes have
impaired immunity pre-operatively?
The relationship between diminished pre-operative
immunity to endotoxin and post-operative complications
was described over 20 years ago both in patients under-
going coronary artery bypass grafts (CABG) and in a
separate study on patients undergoing cardiac valve re-
placement surgery (Bennett-Guerrero et al., 1997;
Hamilton-Davies et al., 1997).
It is possible that the inverse relationship between
pre-operative antibody levels and outcome following cardiac
surgery may pertain to all peri-operative antigenic/infective
threats. Identifying factors that predispose or protect against
post-operative infection may allow mitigation of that risk.
It is important to understand the underlying relationship
between pre-operative staphylococcal antibody levels and
post-operative outcome before hypothesising and testing
whether the pre-operative levels can be altered and whether
this subsequently leads to an improved outcome.
In this study, we aimed to determine if the relationship
between pre-operative anti-staphylococcal antibodies and
outcome in patients undergoing aortic valve replacement
was similar to that previously seen with pre-operative
EndoCAb levels. In addition, it was intended to reconfirm
the EndoCAb relationship with outcome and examine
these relationships with an antibody not thought to be




The patients in this study were a convenience sample as
a sub-group of a larger study (NCT02174471) looking at
myocardial structure of patients undergoing aortic valve
replacement with or without additional procedures.
Ethical approval for this study was given by the NRES
Committee, London (Ref No 07/H0715/101).
Patients scheduled for aortic valve replacement were
approached and verbal and written consent to participate
was obtained from those willing to take part in the study.
No individual identifiable data is included in this submis-
sion. We aimed to include all patients from the parent
study who had undergone first-time isolated AVR.
Exclusion criteria were age under 18 years, recent or on-
going infection, pregnancy, an immunosuppressive condi-
tion and concomitant use of immunosuppressive therapy.
Following recruitment, prior to surgery, the patient
was venesected and blood samples centrifuged for
15 min at 3000 rpm and the serum stored in cryotubes
(Thermoscientific, Mass) at − 80 °C for later analysis.
We chose to assay for antibodies to the extracellular
polypeptides alpha-toxin (AT) and staphylococcal entero-
toxin A (SEA), and to teichoic acid (TA), a major surface
antigen of the staphylococcal organism; all are present in
almost all strains of Staphylococcus aureus. A high propor-
tion (86–95%) of the S. aureus isolates in clinical infections
produce an anti-alpha-toxin antibody response (Granstrom
et al., 1983a). In cases of serious staphylococcal infection,
the levels of alpha-toxin have been demonstrated to be
very high, suggesting that the antigen is highly immuno-
genic (Colque-Navarro et al., 1993). Teichoic acid is par-
ticularly expressed in case of long-standing staphylococcal
infection, for example, deep-seated wound infection or
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endocarditis (Colque-Navarro et al., 1998). It was also de-
cided to assay for SEA antibodies as this toxin is the most
commonly produced enterotoxin in S. aureus strains
(Kanclerski et al., 1996). These three antibodies are likely
to be reliably expressed in those patients undergoing car-




The ELISA procedure for assaying alpha-toxin, teichoic
acid, and staphylococcal enterotoxin A antibody levels
has been detailed previously (Granstrom et al., 1983b;
Colque-Navarro et al., 2000). Briefly, coating doses for
the 96-well microtitration plates (Dynatech M-129B,
Plochingen, Germany) with alpha-toxin, teichoic acid
and SEA were established at 2.5 μg/mL, 1 μg/mL and
0.5 μg/mL, respectively. The working volume through-
out the tests was 100 μL/well. The microtitration plates
were coated with antigens diluted in phosphate-buffered
saline (PBS), pH 7.4, and incubated overnight at 22 °C.
The plates were washed and a serum dilution in PBS
with Tween-20 0.05% v/v (PBS-T) of 1 in 1000 for
α-toxin and SEA and 1 in 10,000 for teichoic acid was
added to two coated wells. Positive and negative controls
were included in each plate. The plates were incubated
for 1 h at room temperature (20 °C). After washing the
plates, alkaline phosphatase-conjugated goat anti-human
antibody (Sigma) diluted in PBS-T was added to each
well, and the plates were incubated for 2 h at room
temperature. After the final wash, p-nitrophenyl- phos-
phate substrate (Sigma) was added. Titres were read
when the positive controls reached previously estab-
lished values at 405 nm on a Titertek Multiskan (Flow
Laboratories, Irvine, Scotland) instrument.
The antibody levels were expressed as arbitrary
units by using the reference line unit calculation
method (Reizenstein et al., 1995).
EndoCAb analysis
Serum EndoCAb levels were measured with an ELISA
using equimolar amounts of a lipopolysaccharide
(LPS) from each of a selected Escherichia coli, Salmon-
ella typhimurium, Klebsiella aerogenes, Pseudomonas
aeruginosa rough mutant strain, lacking the LPS
O-polysaccharide and part of the LPS outer core, but
retaining the inner core structure. These were each
complexed to polymyxin B, mixed in a cocktail in car-
bonate-bicarbonate buffer (pH 9.6), and the cocktail
coated on 96-well polystyrene microtitre plates
selected for optimal EndoCAb ELISA characteristics.
Results are expressed as median units (MU) per milli-
litre, where 100 MU/mL is the median value of a
population of 1000 healthy volunteers.
Test and control samples were diluted 1:200 with dilu-
tion buffer, and 100 μl of each sample to be assayed was
added in triplicate to the wells of a pre-coated microtitre
plate. The assay was standardised using a calibrated
pooled-serum standard of a predetermined EndoCAb
IgG concentration. An eight-point standard curve was
constructed using doubling dilutions of the calibrated
serum, which gave a range of IgG EndoCAb of 12.25 to
784 MU, and 100 μl of each added in triplicate to the
microtitre plate. Following the addition of the samples
and standards, the plate was covered and incubated for
1 h at 37 °C.
The plates were then washed three times with phosphate-
buffered saline solution-polysorbate (Tween) buffer (sodium
chloride, 0.138 M; phosphate, 0.01 M; pH 7.4 containing
0.10% [v/v] polyoxyethylene sorbitan monolaurate [Tween
20]) and finally blotted dry.
An alkaline phosphatase goat anti-human IgG anti-
body (Sigma-Aldrich Chemical Co; Poole, UK) was
diluted 1:500 with dilution buffer, and 100 μl of conju-
gated antibody was added to each well; the plates were
covered and incubated for 1 h at 37 °C.
After incubation, the plates were washed three times
with Tween buffer. Substrate (100 μl), comprising 1 mg/
mL disodium p-nitrophenyl phosphate in 0.05 M sodium
bicarbonate; 0.05 M sodium carbonate 2:1 (v/v) contain-
ing 0.002 M magnesium chloride, was added to each
plate and incubated at room temperature in the dark for
approximately 30 min.
The plate was then read at 405-nm wavelength using
an automated plate reader (Anthos Labtech; Salzburg,
Austria). A standard curve was constructed at 405 nm
against EndoCAb concentration, and the result of test
samples was deduced from the curve. Results were
rejected if the EndoCAb concentration of the control
sample varied > 1 SD from its assigned value or the cor-
relation coefficient for the standard curve was < 0.98.
VZV antibody analysis
These were assayed using a semi-quantitative test
which enabled the positioning of the antibody levels
relative to the other samples being tested (Biomerieux,
Basingstoke, UK). The assay principle combines a
two-step enzyme immunoassay sandwich method with
a final fluorescent detection––enzyme-linked fluores-
cent assay (ELFA).
The solid-phase receptacle (SPR) acts as the solid
phase, as well as the pipetting device. The reagents are
ready-to-use and dispensed in the sealed reagent strips.
The instrument performs all of the assay steps automat-
ically, with the reaction medium being cycled in and out
of the SPR several times.
After a preliminary wash step and dilution in the sam-
ple diluent, the sample is incubated in the SPR. Any
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anti-VZV antibodies present in the sample will bind to
the VZV antigen coating on the interior of the SPR. Un-
bound components are removed in the subsequent wash
step. Anti-human IgG antibodies conjugated with alka-
line phosphatase will bind to any human IgG bound to
the interior of the SPR. Washing removes unbound con-
jugate. During the final detection step, the substrate
(4-methyl-umbelliferyl phosphate) is cycled in and out of
the SPR. The bound conjugate enzyme present catalyses
the hydrolysis of the substrate into a fluorescent product
(4-methyl-umbelliferone), which is measured at 450 nm.
The intensity of the fluorescence is proportional to the
concentration of anti-VZV IgG antibodies in the sample.
This value is automatically compared to the calibration
curve and a result printed.
The result for each sample is expressed as the ‘test
value’ (TV), a ratio of the ‘relative fluorescence
value’ (RFV) of the sample to that of the stored
value of the standard.
TV ¼ RFV of sampleRFV of standard stored on system
Pre-operative risk scoring
EuroSCORE 2 values were obtained for each patient along
with demographic information including age, gender,
height, weight, body mass index, left ventricular ejection
fraction, peak gradient across the aortic valve, presence of
diabetes, presence of hypertension, NYHA class and glom-
erular filtration rate. All patients underwent routine screen-
ing prior to surgery for evidence of colonisation with
methicillin resistant Staphylococcus aureus.
Diabetes was considered present if the patient had a
pre-operative requirement for oral hypoglycaemic or insulin
therapy. Left ventricular ejection fraction (LVEF), peak gra-
dient across the aortic valve and estimated aortic valve area
(AVA) were determined by standard 2D echocardiography
performed within 6 weeks prior to surgery.
Outcomes
The primary outcome measure was post-operative length
of stay in hospital. Secondary outcomes included length of
stay on ICU, development of infection and mortality at
30 days. Peri-operative outcome data was collected regard-
ing length of cardiopulmonary bypass, aortic close-clamp
time, length of stay on the ICU, and on the development of
infection, as well as survival up to 30 days. We used the
Centre for Disease Control and Prevention (CDC) and
National Healthcare Safety Network (NHSN) guidance to
define the presence of a healthcare-associated infection
(HAI) (Horan et al., 2008). Attributing whether or not there
was a significant post-operative infection was determined
by examining the following characteristics: We noted for all
patients the clinical judgement by staff directly caring
for the patient, direct observation of patients and
wounds, and blood and microbiology laboratory re-
sults, whether samples were sent for culture of patho-
genic organisms, whether any positive result was
obtained, whether an antimicrobial agent was started
and whether the clinical teams determined that there
was a (HAI).
All patients received standard institutional antibiotic
prophylaxis consisting of 1 g flucloxacillin and 1.5 mg/
kg gentamicin.
Statistical analysis
Data are presented as absolute numbers and percentages
for categorical variables and median and interquartile
range for continuous variables. Continuous variables
were compared by t tests and Mann-Whitney U tests
whereas dichotomous variables were compared using
Fisher’s exact test. Probabilities are two-tailed.
Given an average length of post-operative stay in our
institution for uncomplicated valve surgery of 7 days,
and a stay of 10 days or greater being considered pro-
longed (Bennett-Guerrero et al., 1997), we estimated
that, at 80% power, with a 5% type II error rate, a sample
size of 21 in each group would be sufficient to detect a
3-day increase in length of stay. This would require us
to examine 84 patients in order to have sufficient num-
bers in each quartile.
After losing 32 patients from the initial cohort, we
performed post hoc power calculations based on the
demonstrated reduction in length of stay from 10 to
6 days. With 15 subjects in each quartile group, we are
able to detect the change in length of stay with 80%
power and 5% type II error rate. In a previous study
comparing pre-operative EndoCAb levels, significant dif-
ferences in outcome were demonstrated in a cohort of
60 patients (Hamilton-Davies et al., 1997).
Results
A total of 149 patients were recruited in the parent trial,
and 94 of these had isolated AVR. Sixty of these who
underwent isolated first-time AVR had complete data
with respect to available serum, blood analysis results
and post-operative outcome information. Thirty-four pa-
tients did not have completed analysis of serum. There
were no exclusions of recruited patients with complete
data from the analysis.
Pre-operative characteristics and relevant intra-operative
variables of the study population are presented in Table 1.
Patients with lower pre-operative antibody levels ap-
peared to have a longer post-operative stay following aortic
valve replacement.
Post-operative outcome data is presented in Table 2.
The median (IQ range) post-operative length of stay for
the whole group was 8 (Nashef et al., 1999; Wang et al.,
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2014; Kanafani et al., 2009; Bennett-Guerrero et al.,
1997; Hamilton-Davies et al., 1997) days, and there were
no in-hospital deaths. One patient died 13 days follow-
ing discharge from hospital. The relationship between
antibody levels to endotoxin core and to the three
staphylococcal epitopes and outcomes are given in Fig. 1.
The relationship between VZV antibodies and outcomes
are given in Fig. 2.
For each antibody assay the results for all patients
were ranked in ascending order from 1 to 60; thus, each
participant had an indication of the relative ranking of
each antibody level result ranging from 1 to 60. The
antibody level rankings for the EndoCAb and the three
anti-staphylococcal assays were added to create a cumu-
lative antibody level ranking for each patient. The group
of 60 patients were then divided into quartiles based on
the cumulative ranking of antibody levels. Figure 3
shows the length of stay and EuroSCORE II for each
quartile within this group. The median values for various
demographic parameters for each quartile of the ranked
group are shown in Table 3.
Fourteen patients were deemed as having a clinically
significant infection (median LOS 11 days) compared with
the 46 patients who were not deemed to have infection
(median LOS 7 days) (p = 0.0033). Three of the 14 returned
positive microbiology cultures (1 Staphylococcus aureus
wound infection, 1 Staphylococcus epidermidis wound
infection and one Escherichia coli wound infection). The
remaining 11 patients with no positive microbiology culture
result had abnormal CRP and WCC profiles along with
clinical suspicion of infection and were each started on
antibiotic therapy. In total, 6 patients developed a wound
infection of which one was a primary deep incisional infec-
tion and the remaining were superficial infections. Eight
patients developed a chest infection (PNU1 type). We were
unable to determine a relationship between individual anti-
body levels and the likelihood of developing a clinically
significant infection. However, with the analysis of com-
bined antibody group, there appeared to be an association
between pre-operative antibody levels and the likelihood of
developing a post-operative HAI (Table 4).
Discussion
The results from this study suggest a relationship be-
tween pre-operative staphylococcal antibody levels and
outcome following aortic valve surgery. This result ap-
pears to be similar to previously published relationships
between EndoCAb levels and outcome after cardiac sur-
gery. Our study reconfirms that relationship between
pre-operative EndoCAb levels and length of stay follow-
ing cardiac surgery.
Several studies have now demonstrated the link between
pre-operative immune status to endotoxin and outcome
following major surgery (Bennett-Guerrero et al., 1997;
Hamilton-Davies et al., 1997; Bennett-Guerrero et al.,
2001). Endotoxin exposure is common during cardiopul-
monary bypass (CPB) (Andersen et al., 1987) and may be
due to translocation across the bowel as a consequence of
episodes of presumed hypo-perfusion. The protective ability
of antibodies to this may not be surprising, yet the innate
immunity of the pre-operative patient is not routinely ex-
plored, and is not incorporated in standard risk assessment
algorithms. Endotoxin and Gram-negative organisms are
not the only peri-operative threat that patients undergoing
CPB are potentially exposed to in the peri-operative phase
with staphylococcal wound infection complicating some 3–
4% of cardiac procedures (Fowler Jr. et al., 2005). A large
study carried out in the USA on over 8000 patients under-
going cardiopulmonary bypass surgery found an overall
mortality rate of 4% compared with over 17% for those de-
veloping post-operative MRSA (Allen et al., 2014). The eco-
nomic implications of cardiac surgical patients developing
Table 1 Subject characteristics
Number 60
Age (years) 73 (66–78)
Male (%) 34 (57)
BMI (kg m−2) 27.7 (24.6–31.3)
LVEF (%) 73 (66–79)
Aortic Valve Peak gradient (mmHg) 75 (63–88)
Diabetes mellitus (%) 11 (18)
Hypertension (%) 49 (82)
NYHA
Class I 10 (17)
Class II 34 (57)
Class III 14 (23)
Class IV 2 (3)
GFR (ml min−1) 72 (56–88)
EuroSCORE II 1.44 (0.95–1.99)
CPB time (min) 81 (71–106)
Aortic cross clamp time (min) 60 (53–73)
Data are presented as number of patients and percentage within the group or
as median and interquartile range
BMI body mass index, LVEF left ventricular ejection fraction, NYHA New York
Heart Association, GFR glomerular filtration rate, CPB cardiopulmonary bypass time
Table 2 Outcome characteristics
Number 60
Length of stay in ICU (days) 2.5 (2–4)
Length of post-operative stay in hospital (days) 8 (6–10)
Development of significant infection 14 (23)
Death (in hospital) 0
Death (within 30 days) 1 (1.7)
Data are presented as number of patients and percentage within the group or
as median and interquartile range
ICU intensive care unit
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staphylococcal bacteraemia is great with a three-fold
increase in cost for the group developing infective complica-
tions (Brown et al., 2008; Coskun et al., 2005).
The variability in anti-staphylococcal antibodies in
healthy volunteers and in pre-operative surgical pa-
tients has been demonstrated (Moravcova et al., 2016;
Colque-Navarro et al., 2010) and that variability in the
surgical patients appears to be greater than that in a
healthy volunteer population (Moravcova et al., 2016).
Much work has been performed on antibodies to
various staphylococcal epitopes and, in particular, how
these levels are related to certain infective or inflam-
matory clinical situations (Kanclerski et al., 1996).
Antibodies to alpha-toxin and teichoic acid have been
shown to relate to development of complications during
staphylococcal septicaemia with lower initial levels relat-
ing to a poorer antibody response (Colque-Navarro et al.,
1998).
Not only is staphylococcus the major organism re-
sponsible for cardiac surgical site infections (SSIs), it has
also been shown that the alpha-toxin fragments secreted
by staphylococcus can impair gut mucosal integrity
(Kwak et al., 2012). This may further worsen the poten-
tial for sepsis by enabling Gram-negative organism or
endotoxin translocation from the gut lumen to the
bloodstream (Swank & Deitch, 1996).
Fig. 1 Patient cohort divided into quartiles for each measured antibody level. The median antibody level for each quartile is given. Median length
of post-operative stay for each quartile (bars) and trend-line (blue line) and the median EuroSCORE II (number, yellow dot) is displayed for each
group. (Q1––quartile 1, etc.)
Fig. 2 Patient cohort divided into quartiles for measured antibody level to varicella-zoster virus (VZV). The median antibody level for each quartile
is given. Median length of post-operative stay for each quartile (bars) and trend-line (blue line) and the median EuroSCORE II (number, yellow
dot) is displayed for each group. (Q1––quartile 1, etc.)
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As with previous EndoCAb studies, this study has dem-
onstrated that an inverse outcome relationship also exists
for antibody levels to staphylococcus, another peri-operative
threat. A relationship could not be established with antibody
levels to varicella, a threat not encountered in the operative
environment. This raises a question as to whether the out-
come relationship only holds for antibodies to peri-operative
threats. It is possible that some patients have an impaired
immunological ability to react to these encountered threats
and, when they are challenged, are unable to mount a
suitable immune response resulting in adverse post-
operative recovery.
The patients with low levels of several antibody types
appear to have worse outcomes than those with low
levels in only one type or higher levels in all types.
Our study suggests that pre-operative immunity may
impact on post-operative outcome. Current commonly
used risk scoring methods do not take any account of
immune competence (Nashef et al., 2012). If immunity
is important, then it follows that an assessment of im-
mune system competence should be incorporated into
those risk stratification processes to allow more accurate
risk profiling and consequently a more informed discus-
sion with the patient whilst considering surgical options
for heart disease.
It is important to note that these conclusions are being
drawn from observational data collected from a rela-
tively small number of patients with a moderate degree
of variability in the pre-operative characteristics. Due to
the small study size, little conclusion can be drawn as to
whether developing infectious complications is associ-
ated with antibody levels. Moreover, antimicrobial ther-
apy is often started empirically, before culture results are
known, confounding the standardised definitions of
presence of infection. We have no information regarding
immune responsiveness at the cellular level and are
making an assumption that pre-operative antibody levels
reflect immune responsiveness at some level. Immune
responsiveness is a dynamic process, and we are measur-
ing antibody levels at one time point. The staphylococcal
antibodies that we chose to study have previously been
Fig. 3 Patient cohort divided into quartiles for combined, ranked antibody levels for the four antibodies. Median length of post-operative stay for
each quartile (bars) and trend-line (blue line) and the median EuroSCORE II (number, yellow dot) is displayed for each group. (Q1––quartile 1, etc.)
Table 3 Outcome characteristics for the combined rank group
Q1 Q2 Q3 Q4 Q1 vs Q4
Number 15 15 15 15
Age (years) 74 71 75 70 p = 0.289
BMI (kg m−2) 26.2 26.9 25.7 28.1 p = 0.342
LVEF (%) 73 72 77 69 p = 0.908
EuroSCORE II 1.64 1.47 1.21 1.42 p = 0.429
CPB time (min) 85 77 78 89 p = 0.392
Aortic cross clamp time (min) 59 58 61 62 p = 0.313
Length of stay in ICU (days) 3 4 2 2 p = 0.348
Post-operative stay (days) 10 8 7 6 p = 0.017
Proportion with infection 0.33 0.33 0.27 0 p = 0.042
Death 0 0 1 0
Data are presented as median for each quartile (Q1–Q4). The proportion with
infection is displayed as the proportion of the quartile group who developed
an infection
BMI body mass index, LVEF left ventricular ejection fraction
Table 4 Percentage within each quartile for each antibody type
and for the ranked antibody group that developed a clinically
significant infection
Q1 Q2 Q3 Q4
Number 15 15 15 15
Teichoic acid 33.3% 26.7% 13.3% 20% p = 0.682
Alpha-toxin 40% 20% 13.3% 20% p = 0.427
Staphylococcal enterotoxin A 13.3% 20% 46.7% 13.3% p = 1.000
EndoCAb 26.7% 33.3% 6.7% 26.7% p = 1.000
4-way rank 33% 33.3% 26.7% 0% p = 0.042
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associated with outcome studies, but there many epi-
topes that are as yet unexplored and which may have a
greater or lesser contribution to effects on outcome. We
chose to use post-operative length of stay (LOS) as the
main measure of outcome in this study in order to allow
comparison with similar previously published work. LOS
is readily understood by patients and clinicians and re-
flects a composite outcome accounting for multiple
post-operative complications. Other non-clinical prob-
lems may well impact on LOS (e.g. failure to reach ad-
equate anticoagulation, social care needs), and there may
be benefit for future studies to explore the specific mor-
bidity domains that impact on LOS, e.g. CPOMS (Sanders
et al., 2012).
If the patient is thought to be at elevated risk of adverse
outcome as a consequence of impaired immunity, is there
an alternate treatment option that has less risk? It is not yet
known whether transcatheter procedures, for example
transcatheter aortic valve replacement (TAVR) (Moat et al.,
2011), expose the patient to the same level of antigenic
threat compared to open surgery. It may be that a TAVR is
a preferred option for some patients judged to be at higher
risk because of their immune system performance.
Can the risk conferred by impaired immune perform-
ance be altered? The association of low levels of antibody
to both staphylococcus and endotoxin may indicate that
pre-operative elevation of these could be a potential thera-
peutic strategy and this might be enabled by either active
or passive immunisation. We have previously demon-
strated that pre-operative EndoCAb elevation is possible
both actively and passively (Hamilton-Davies, 1998;
Hamilton-Davies et al., 1996). Active vaccination may
offer some benefit; however, it is likely to be a less effective
strategy in a patient who has an impaired immune
response.
Anti-endotoxin therapies have been tried in sepsis
and failed to consistently show benefit in clinical trials
(McCloskey et al., 1994; Bone et al., 1995). One ques-
tion arising from these studies has been whether the
products are being correctly targeted at the patient
population groups. Treatment in sepsis at time zero is
often not feasible, and the underlying immune status of
the treatment group is not known. Major elective sur-
gery with a reasonably high-mortality/morbidity out-
come profile would seem to allow for a much more
controlled study environment and is also the originat-
ing population for a proportion of those developing
sepsis and multiple organ failure (MOF). Surgical site
infection (SSI) following cardiac surgery is often a pri-
mary negative event that precipitates a progression of
events terminating in MOF and death (Allen et al.,
2014). The major infective elements contributing to
SSIs are represented by staphylococcal organisms and
Gram-negative organisms (up to 35%) containing the
pro-inflammatory components of the endotoxin core
(Soderquist, 2007; Garey et al., 2006). These may also
contribute to the development of post-operative
ventilator-associated pneumonia (VAP) (Hortal et al.,
2009; Kollef et al., 1997).
Targeting of potential therapeutic agents towards those
that can be shown to be ‘at risk’ due to lower
pre-operative levels of protective antibodies against
endotoxin core and staphylococcal epitopes along with
other conventional risk criteria may enable a clearer
assessment as to their efficacy.
It is currently not known if the antibody levels measured
pre-operatively are temporarily low or chronically low due
to a hypo-responsive immune system and whether it is
chronic immune hypo-responsiveness that is the real issue
associated with a poor outcome. It is possible that the
chronic immune hypo-responsiveness may be genetically
determined; and thus, these patients may not be expected
to benefit from active immunisation. It may be that they
would fall into the same population of patients that are
observed to succumb to secondary sepsis (van Vught et
al., 2016) and that have been linked to the genetic signa-
ture associated with endotoxin tolerance (Pena et al.,
2014; Cavaillon & Adib-Conquy, 2006). Determining the
answer to these questions will allow a more precise defin-
ition of the at risk group and, in combination with other
conventional risk scoring systems incorporating oxygen
delivery profiles, will probably lead to a more comprehen-
sive risk analysis.
Conclusion
This study suggests an apparent association between
pre-operative antibody levels and outcome following car-
diac surgery. An inverse relationship is seen between out-
come following AVR and pre-operative antibody levels to
staphylococcus and endotoxin, important peri-operative
threats. There is no such relationship for antibody
levels against an organism not thought to pose a peri-
operative threat.
The result supports our assertion that this area deserves
further exploration and investment. Understanding this re-
lationship may enable therapeutic manipulation of immune
status, re-evaluation of peri-operative risk and further in-
vestigation of the low immune state.
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